Healthcare >> CEO Interviews >> January 10, 2001

Brian Gallagher – Collagenex Pharmaceuticals Inc (cgpi)

BRIAN M. GALLAGHER is currently Chairman, President and Chief Executive Officer of CollaGenex Pharmaceuticals, Inc., a publicly traded, profitable, specialty pharmaceutical company located in Newtown, Pennsylvania. Dr. Gallagher also currently serves as a Director of Adams Laboratories, Inc., a privately held, specialty pharmaceutical company in the respiratory and allergy fields and ImaRx Therapeutics, Inc., a privately held, drug delivery/specialty pharmaceutical company with an initial focus on cardiovascular disease. He was also formerly a Director of Acusphere, Inc., a privately held, drug delivery technology company. Dr. Gallagher was formerly President of Squibb Diagnostics, a division of Bristol-Myers Squibb Company in Princeton, New Jersey, from 1991 until joining CollaGenex in 1994. Prior to that, he served in various executive management positions, including Vice President of Marketing and Worldwide Business Development at Bristol-Myers Squibb. From 1978 until 1988, Dr. Gallagher served with increasing responsibilities in various research, development, business development and marketing positions with the Pharmaceuticals Division of E.I. du Pont de Nemours Company, Inc. and its predecessor New England Nuclear Corporation. Prior to DuPont, from 1974 until 1978, Dr. Gallagher served as a Research Scientist in the Chemistry Department of Brookhaven National Laboratory. He is the author of numerous scientific publications, review articles and book chapters. Dr. Gallagher holds a Bachelor of Science degree in Biology from St. Louis University (1969), a Master of Science degree in Marine Science from Long Island University (1971) and a Doctor of Philosophy degree with a concentration in Biochemistry and Cell Physiology (1974) from St. John's University. Profile
TWST: Could we start out with a history and a quick overview of

CollaGenex?

Dr. Gallagher: CollaGenex is a specialty pharmaceutical company focused

on providing new therapies not only to the